These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12473574)

  • 1. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
    Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
    Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
    Held LA; Rizzieri D; Long GD; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Horwitz ME; Chao NJ; Gasparetto C
    Cancer Invest; 2013 Mar; 31(3):172-6. PubMed ID: 23406188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
    Berenson JR; Swift RA; Ferretti D; Purner MB
    Clin Lymphoma; 2004 Sep; 5(2):130-4. PubMed ID: 15453931
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
    Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
    Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
    Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
    Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
    Borad MJ; Swift R; Berenson JR
    Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
    Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
    Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
    Abou-Jawde RM; Reed J; Kelly M; Walker E; Andresen S; Baz R; Karam MA; Hussein M
    Med Oncol; 2006; 23(2):263-72. PubMed ID: 16720927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    Cavenagh J; Oakervee H; Baetiong-Caguioa P; Davies F; Gharibo M; Rabin N; Kurman M; Novak B; Shiraishi N; Nakashima D; Akinaga S; Yong K
    Br J Cancer; 2017 Oct; 117(9):1295-1302. PubMed ID: 28873084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
    Chang JE; Voorhees PM; Kolesar JM; Ahuja HG; Sanchez FA; Rodriguez GA; Kim K; Werndli J; Bailey HH; Kahl BS
    Hematol Oncol; 2009 Mar; 27(1):11-6. PubMed ID: 18668698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
    Aldoss I; Mark L; Vrona J; Ramezani L; Weitz I; Mohrbacher AM; Douer D
    Ann Hematol; 2014 Nov; 93(11):1839-43. PubMed ID: 24906216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
    Hofmeister CC; Jansak B; Denlinger N; Kraut EH; Benson DM; Farag SS
    Leuk Res; 2008 Aug; 32(8):1295-8. PubMed ID: 18082257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.
    Isoda A; Ishikawa T; Miyazawa Y; Mihara M; Matsumoto M; Sawamura M
    Leuk Lymphoma; 2018 May; 59(5):1277-1278. PubMed ID: 28874073
    [No Abstract]   [Full Text] [Related]  

  • 20. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
    Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
    Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.